Kite Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Kite Pharma's estimated annual revenue is currently $1.2B per year.
- Kite Pharma received $356.2M in venture funding in March 2017.
- Kite Pharma's estimated revenue per employee is $248,000
- Kite Pharma's total funding is $85.3M.
Employee Data
- Kite Pharma has 4981 Employees.
- Kite Pharma grew their employee count by 8% last year.
Kite Pharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Admin Coordinator for VP Clinical Development | Reveal Email/Phone |
2 | VP Clinical Operations and Data Management | Reveal Email/Phone |
3 | Head Commercial IT - Global (Interim) | Reveal Email/Phone |
4 | Head Finance | Reveal Email/Phone |
5 | SVP & Global Head Commercial | Reveal Email/Phone |
6 | Head, Process Development Team Leads | Reveal Email/Phone |
7 | VP and Head Global Portfolio and Program Strategy | Reveal Email/Phone |
8 | VP, U.S. Marketing | Reveal Email/Phone |
9 | Head Corporate Legal | Reveal Email/Phone |
10 | VP, Clinical Development | Reveal Email/Phone |
Kite Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Kite Pharma?
Kite, a Gilead company, is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. This mission is at the heart of everything we do, from early research to product development. For the past three decades, members of our team have been at the forefront of cancer immunotherapy. Today, we are a leader in engineered T cell therapy, changing the paradigm of cancer treatment with what is potentially the biggest breakthrough since the introduction of combination chemotherapy more than 60 years ago. With an unrelenting drive and a singular focus on cell therapy, our team is executing on our strategy to bring life-saving therapies to patients. In all areas of the company, we are looking for the very best people who share our deep passion to cure cancer. We realize that our ambitious goals can only be achieved if every employee is fully committed to our mission and embraces our entrepreneurial spirit. If this describes you, please contact us. Our corporate headquarters are in Santa Monica, California.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$85.3M
Total Funding
4981
Number of Employees
$1.2B
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Kite Pharma News
Kite Pharma's Urbana cell therapy manufacturing facility has received federal approval for commercial production of its treatment for blood...
Gilead Sciences' Kite Pharma has further beefed up its cell therapy manufacturing footprint fresh on the heels of an FDA go-ahead for Yescarta as the first...
Santa Monica-based Kite Pharma, a subsidiary of biopharma giant Gilead Sciences, announced on Friday that it has received approval from the Food and Drug...
Draper signed an agreement with Kite, a Gilead Company, to accelerate development of cancer immunotherapies. Pictured is a device concept of Draper’s transduction system. Credit: Draper. “Over the next decade, cell and gene therapies are poised to make groundbreaking improvements in health care ...
Other Companies in Santa Monica
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2395.4M | 6204 | -5% | $233.5M |
#2 | N/A | 12633 | 2% | $7.8B |
#3 | $672.7M | 28124 | 8% | $279M |
Kite Pharma Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2011-03-10 | $15.0M | Undisclosed | Riverbank Capital Securities I | Article |
| 2013-05-16 | $35.0M | Undisclosed | Article | |
| 2014-04-29 | $50.0M | Undisclosed | Article | |
| 2017-03-03 | $356.2M | Undisclosed | Jefferies LLC | Article |